BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9625331)

  • 21. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height.
    Lazar L; Kauli R; Pertzelan A; Phillip M
    J Clin Endocrinol Metab; 2002 May; 87(5):2090-4. PubMed ID: 11994346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty.
    Saggese G; Bertelloni S; Baroncelli GI; Battini R; Franchi G
    Eur J Pediatr; 1993 Sep; 152(9):717-20. PubMed ID: 8223799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
    Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Near final height after GnRH agonist treatment in central precocious puberty.
    Micillo M; Salerno M; Officioso A; Perna E; Gasparini N; Pisaturo L; Di Maio S
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():787-90. PubMed ID: 10969922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GH and GnRH analog treatment in children who enter puberty at short stature.
    Tanaka T; Satoh M; Yasunaga T; Horikawa R; Tanae A; Hibi I
    J Pediatr Endocrinol Metab; 1997; 10(6):623-8. PubMed ID: 9467133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment].
    Messaaoui A; Massa G; Tenoutasse S; Heinrichs C
    Rev Med Brux; 2005 Feb; 26(1):27-32. PubMed ID: 15816337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment.
    Adan L; Chemaitilly W; Trivin C; Brauner R
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):297-302. PubMed ID: 11940040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
    Gillis D; Karavani G; Hirsch HJ; Strich D
    J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.
    Shim YS; Lim KI; Lee HS; Hwang JS
    PLoS One; 2020; 15(12):e0243212. PubMed ID: 33301485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central precocious puberty: current treatment options.
    Antoniazzi F; Zamboni G
    Paediatr Drugs; 2004; 6(4):211-31. PubMed ID: 15339200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment with LHRH analogues in girls with precocious puberty does not improve final height. Longitudinal study compared with a control group].
    Llop-Viñolas D; Vizmanos-Lamotte B; Aresté-Piztzalis A; Fernández-Ballart J; Martí-Henneberg C
    Med Clin (Barc); 2001 Jun; 117(4):124-8. PubMed ID: 11472683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
    Guaraldi F; Beccuti G; Gori D; Ghizzoni L
    Eur J Endocrinol; 2016 Mar; 174(3):R79-87. PubMed ID: 26466612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.